Khiron Life Sciences has received authorization from Colombia's National Narcotics Fund for the sale of magistral preparation of high-THC medical cannabis. With this authorization Khiron becomes the first and, to date, only company fully authorized to manufacture and sell high-THC medical cannabis for patient prescriptions in Colombia.
"The authorization from Colombia's National Narcotics Fund demonstrates our continued ability to meet regulatory requirements, and as a result we today begin to sell high-THC medical cannabis product in Colombia. With our clinics, training and infrastructure in place our high-THC product offers an important alternative for patients living with chronic pain, nausea and vomiting associated with chemotherapy, and continues Khiron's mission to improve the quality of life for patients in Colombia and across Latin America," comments Juan Diego Alvarez, Khiron Vice-President of Regulatory Affairs.
Initial high-THC product prescriptions under the National Narcotics Fund authorization will be filled through the Company's fully owned ILANS clinics which are in receipt of high-THC dispensary authorization. Distribution will expand as Khiron's Colombian pharmacy partners receive dispensing authorization, which is anticipated in Q3 2020.
For more information:
Khiron Life Sciences Corp.
khiron.ca